Email Print this page Bookmark this page


LACRISERT® is a small, translucent ophthalmic insert that is administered into the inferior cul-de-sac of each eye. Once inserted, LACRISERT® gently begins to dissolve within minutes.1

For most patients with moderate to severe Dry Eye, one LACRISERT® in each eye once daily will suffice. However, some patients may require LACRISERT® twice a day to relieve their symptoms.1

LACRISERT® releases a thin layer of cellulosic polymer over the ocular surface, stabilizing the compromised tear film.2 LACRISERT® retains fluid on the ocular surface, allowing your patient’s natural tears to be preserved throughout the day.3 As the tear film thickens, it is able to remain on the ocular surface longer, providing better protection and relief from Dry Eye symptoms.1

LACRISERT® has been proven to relieve the following symptoms1,3:

  • Dryness
  • Hypersensitivity
  • Smarting
  • Itchiness
  • Burning
  • Excessive tearing
  • Foreign body sensation
  • Exudation
  • Photophobia
  • Blurred vision
  • Conjunctival hyperemia

While most patients usually begin to experience amelioration of their symptoms within 2 weeks of beginning treatment, it may take several weeks for others to improve.1,4,5

Since LACRISERT® requires moisture to begin dissolving, in certain situations, your patients may need to administer artificial tears upon insertion to begin the dissolution process.3,6

The following adverse reactions have been reported with the use of LACRISERT®, but were, in most instances, mild and transient1:

  • Transient blurring of vision
  • Ocular discomfort or irritation
  • Matting or stickiness of eyelashes
  • Photophobia
  • Hypersensitivity
  • Edema of the eyelids
  • Hyperemia

Click here to report any adverse reactions that your patient may have experienced while using LACRISERT®.

Indications and Usage

LACRISERT® is indicated in patients with moderate to severe Dry Eye syndromes, including keratoconjunctivitis sicca. LACRISERT® is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT® is also indicated for patients with exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.

Important Safety Information

LACRISERT® is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose. Instructions for inserting and removing LACRISERT® should be carefully followed. If improperly placed, LACRISERT® may result in corneal abrasion. Because LACRISERT® may cause transient blurred vision, patients should be instructed to exercise caution when driving or operating machinery. Patients should be cautioned against rubbing the eye(s) containing LACRISERT®.

The following adverse reactions have been reported, but were in most instances, mild and temporary: transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, eyelid edema, and hyperemia.

References: 1. Lacrisert [prescribing information]. Lawrenceville, NJ: Aton Pharma, Inc; 2007.
2. Breslin CW, Katz J, Haufman HE, Katz I. Slow release artificial tears. In: Leopold IH, Burns RP, eds. Symposium on Ocular Therapy. New York, NY: John Wiley & Sons; 1977;10:77-83. 3. Katz JI, Kaufman HE, Breslin C, Katz IM. Slow-release artificial tears and the treatment of keratitis sicca. Ophthalmology. 1978;85(8):787-793. 4. Hill JC. Slow-release artificial tear inserts in the treatment of dry eyes in patients with rheumatoid arthritis. Br J Ophthalmol. 1989;73(2):151-154. 5. Lacrisert Clinical White Paper. Available at: Accessed January 5, 2009.
6. HØvding G, Aasved H. Slow-release artificial tears (SRAT) in dry eye disease: report of a preliminary clinical trial. Acta Ophthalmol. 1989;59:842-846.

sample request using Lacrisert video patient tip sheet
©2012 Valeant Ophthalmics, a division of Valeant Pharmaceuticals North America LLC          Bridgewater, NJ 08807